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ABSTRACT
Objectives To investigate delivery of smoking cessation 
interventions, recorded quit attempts and successful 
quitting rates within primary care in smokers with 
depression or severe mental illness (SMI) compared with 
those without.
Design Longitudinal cohort study using primary 
healthcare records.
Setting English primary care.
Participants 882 849 patients registered with 
participating practices recorded as current smokers during 
2007–2014, including three groups: (1) 13 078 with SMI, 
(2) 55 630 with no SMI but recent depression and (3) 814 
141 with no SMI nor recent depression.
Outcomes Recorded advice to quit smoking, referrals 
to smoking cessation services, prescriptions for smoking 
cessation medication, recorded quit attempts and changes 
of smoking status.
Results The majority (>70%) of smokers had recorded 
smoking cessation advice. This was consistently higher in 
those with SMI than the other cohorts of patients, although 
the gap greatly reduced in more recent years. Increases in 
smoking cessation advice over time were not accompanied by 
increases in recorded attempts to quit or changes of smoking 
status. Overall nicotine replacement therapy prescribing by 
general practitioners (GPs) was higher in those with SMI 
(10.1%) and depression (8.7%) than those without (5.9%), but 
a downward time trend was observed in all groups. Bupropion 
and varenicline prescribing was very low and lower for those 
with SMI. Few smokers (<5%) had referrals to stop smoking 
services, though this increased over time, but no significant 
differences were observed between those with and without 
mental health problems.
Conclusions There was no evidence of consistent inequalities 
in access to GP- delivered smoking cessation interventions 
for people with mental health conditions. Smoking cessation 
advice was widely reported as taking place in all groups. In 
order to address the widening gap in smoking prevalence in 
those with poor mental health compared with those without, 
the emphasis should be on addressing the quality of advice 
and support given.
INTRODUCTION
Poor mental health has been shown to 
be the most common single cause of 
disability- adjusted life years lost globally.1 
Studies have found that people with mental 
ill- health have elevated mortality rates2 3 and 
that for those with severe mental illness (SMI; 
schizophrenia, bipolar disorder and other 
non- organic psychoses) this mortality gap 
has been widening over the last decade in 
the UK.4 Smoking is often seen as a means 
of coping with stress and is more common in 
those with poor mental health.5–7 Prevalence 
rates of smoking were 34.1% in those with 
common mental disorders compared with 
19.6% in those without mental health condi-
tions in 2014,8 and higher rates are seen in 
those with SMI (58% in men and 41% in 
women in the UK).7 However, it is a key modi-
fiable risk factor which greatly contributes 
to the excess risk of cardiovascular diseases 
(CVD) and mortality observed in this popu-
lation. It is therefore an important target for 
intervention. There is consistent evidence 
that quitting smoking leads to improvements 
in both mental and physical health.9–11 It 
has also been shown that those with mental 
illness can successfully quit smoking with 
tailored support.8 Effectiveness can be similar 
Strengths and limitations of this study
 ► This is, to our knowledge, the first nationally repre-
sentative study evaluating trends over time in smok-
ing cessation management practices in people with 
depression and severe mental illness compared with 
the general population in English primary care.
 ► Our data set includes robust information on smoking 
cessation prescriptions in primary care in England.
 ► The data set is however limited only to prescribed 
medications and does not include over- the- counter 
nicotine replacement therapy or e- cigarette use.
 ► There is likely to be under- recording of smoking quit 
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to the general population,12 13 with stronger effects seen 
in those with current depression in studies with a phar-
macological smoking cessation treatment than those with 
psychological treatments.13 However, most of these trials 
have been conducted in specialist clinic settings in stable 
populations and findings for longer term outcomes are 
more mixed,13 14 for example, in the SCIMITAR+ trial 
improved quit rates at 6 months are not sustained by 12 
months in people with SMI.14
Since people with mental illnesses are in regular 
contact with their general practice and this is where more 
assertive management of CVD risk factors—including 
smoking cessation—may occur, general practitioners 
(GPs) can play a key role in incentivising and helping 
patients to stop smoking. There is however to our knowl-
edge little literature that has tested the effectiveness of 
interventions for smoking cessation in primary care 
settings for those with mental health problems, with no 
trials in those with SMI and only one in depression.12 13 
It is therefore important to assess the management of 
smoking cessation for people with poor mental health 
in this setting, including both smoking cessation advice 
and evidence- based treatments, and to both carefully 
document patterns of receipt over time and identify 
areas for improvements. Previous research exploring this 
has been limited. A cross- sectional study using English 
primary care data in a single year (July 2009–June 2010) 
reported that around one- half of smokers with a mental 
health diagnosis (including SMI and depression, among 
others) received smoking cessation advice from their GP 
in that year compared with around one- third of smokers 
without a mental health diagnosis.15 This suggests that 
GPs may promote smoking cessation more often in those 
with mental illness, though the content of this advice is 
unknown. Smoking prevalence is changing over time, 
reducing from 29.3% to 19.6% in those without a mental 
health condition and from 44.6% to 34.1% in those with 
a common mental disorder (depression and anxiety 
disorders) between 1993 and 2014 in Great Britain,8 
the latter remaining therefore much higher than in the 
general population.8 16 17 Furthermore, the gap in CVD- 
related mortality for those with mental illness has also 
been rising over time,4 increasing the need to better 
understand primary care management of smoking 
cessation in people with SMI and to inform strategies to 
promote smoking cessation in people with poor mental 
health.
In this study we examined whether, at the point of 
recording or updating smoking status to reflect current 
smoking (ie, when there was an opportunity for smoking 
interventions to be implemented), GPs were more or less 
likely to offer smoking cessation interventions to those 
with depression or SMI compared with those without 
these conditions. We also investigated if this has changed 




Longitudinal cohort study using healthcare records from 
English primary care.
Data source
We used electronic health records from the English GP 
practices that contributed data to The Health Improve-
ment Network (THIN), a large primary care database in 
the UK. Only data that met quality assurance standards18 
were retained for analysis. THIN holds information on 
for example symptoms, diagnoses, referrals, prescribing, 
health indicators (eg, smoking status) and sociodemo-
graphic status. In particular, smoking status has been 
increasingly better recorded19 and is now routinely 
collected by many GPs as part of the Quality Outcomes 
Framework (QOF,20 a pay- for- performance scheme 
which financially rewards general practices for achieving 
specific targets across a range of indicators. Marston et 
al
21 reported that around 84% of patients have had their 
smoking status recorded at least once during the first year 
of registration with a GP practice. THIN contains records 
on the delivery of smoking cessation advice and on quit 
attempts, although recorded quit attempts are likely to 
be incomplete as many will attempt this without seeing 
their GP. Data on smoking cessation pharmacotherapy 
are available for drugs prescribed by GPs. The first- line 
medicines for quitting smoking are nicotine replacement 
therapy (NRT), bupropion and varenicline. The latter 
two are solely issued on prescription, so their recording 
is complete. In contrast, NRT can be bought over the 
counter and, since information about these purchases is 
not captured in THIN, our findings will be confined to 
NRT prescribing within primary care. The lack of data on 
over- the- counter medication in THIN also means that the 
use of e- cigarettes is also not recorded as these electronic 
devices are not available on prescription in the UK.
Study population
We included all patients aged 18 years or over who were 
permanently registered for at least 6 months with a partic-
ipating practice between 1 January 2007 and 30 June 2015 
and had their smoking status updated to ‘current smoker’ 
at least once between the start of the follow- up and 6 
months from the end of it. This was chosen as it indicated 
both a contemporaneous record of their smoking status 
and an opportunity for the GP to deliver a smoking cessa-
tion intervention to that patient. If a patient had multiple 
updates during the study period, one of them was selected 
at random and treated as the index event. We restricted 
the sample to those with at least 6 months of follow- up 
time to allow time for the outcomes to be recorded. The 
beginning of the follow- up was set at the latest of the 
following: 1 January 2007, the patient’s 18th birthday, the 
patient’s date of registration with the practice and 1 year 
after the date the practice achieved an acceptable level of 
data quality.18 The end of the follow- up was the earliest of 
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the patient’s date of death or the last date the practice 
contributed data to THIN.
Outcomes
We considered outcomes to investigate the delivery of 
smoking cessation interventions and any evidence for the 
potential effectiveness of these interventions in terms of 
quit attempts and changes of smoking status. Specifically, 
we looked at whether or not patients had entries in their 
electronic health records for
1. advice to quit smoking,
2. referrals to stop- smoking services,
3. prescriptions for smoking cessation medication (NRT, 
varenicline or bupropion),
4. recorded quit attempts,
5. changes of smoking status to ex- smoker or non- smoker 
within 6 months from the index event, that is, the 
date (or the randomly selected one in case of multi-
ple dates) when the smoking status was recorded as 
current smoker for that individual. Prescriptions for 
smoking cessation medications were identified using 
the relevant British National Formulary codes.22 The 
read code lists for the other four types of outcome 
were created using standard methods23 and were ap-
proved by a GP. Specifically, quit attempts were iden-
tified using codes for changes of smoking status to 
‘ex- smoker’ or ‘non- smoker’, clear quit attempts (eg, 
‘Recently stopped smoking’), referrals to stop- smoking 
services (excluding codes related to referrals which 
were merely offered or declined) and codes indicating 
that the patient was being prescribed drug treatment 
for smoking cessation.
Recorded mental health status
Smokers were grouped into three cohorts of patients 
depending on whether they had
1. a history of SMI, that is, a record of SMI diagnosis at 
any time in their healthcare record,
2. no history of SMI but recent recorded diagnoses or 
symptoms of depression,
3. no history of SMI nor recent recorded diagnoses or 
symptoms of depression.
People with a history of SMI were identified using read 
codes for diagnoses of bipolar disorder, schizophrenia 
and other non- organic psychotic illnesses (eg, delusional 
disorder) or indicating the inclusion on the SMI register. 
Individuals were considered as having had recent episodes 
of depression if during the year prior to the index date, or 
since their registration with the practice if later, they had 
at least one entry in their medical records for symptoms 
or diagnoses of depression. Read codes related to history 
of depression were excluded to avoid historical episodes 
of depression being treated as incident cases.
Statistical analysis
We calculated the proportion of people who had the 
outcomes of interest during the 6- month window 
following the index date. These proportions, along with 
Table 1 Descriptive statistics for the smokers who entered our study
History of SMI Depression No SMI nor depression
Number of patients (row %) 13 078 (1.5%) 55 630 (6.3%) 814 141 (92.2%)
Gender
  Male 7325 (56.0%) 21 439 (38.5%) 431 743 (53.0%)
  Female 5753 (44.0%) 34 191 (61.5%) 382 398 (47.0%)
Age at index date
  Median 45.1 37.7 39.5
  IQR (35.4–56.1) (27.2–48.5) (27.8–53.1)
Interventions within 6 months from index date
  % Advised to quit 80.0% 73.1% 70.3%
  % With referrals to stop smoking services 2.5% 2.5% 2.2%
  % With prescribed antismoking drugs medication:
  NRT 10.1% 8.7% 5.9%
  Bupropion 0.2% 0.4% 0.4%
  Varenicline 1.3% 2.9% 3.4%
Evidence of attempts to quit within
6 months from index date
  % With recorded quit attempts 18.3% 18.2% 16.3%
  % With smoking status change 5.7% 5.9% 6.4%
In case a patient had more than one smoking status update to ‘current smoker’ during the follow- up, we selected one of them at random and 
used it as the index event.
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95% CIs, were stratified by mental health group and were 
derived in relation to the calendar year in which the 
index smoking status update was recorded. Since data 
from patients attending the same GP practice are likely to 
be correlated, the 95% CIs were calculated using robust 
standard errors24 25 to account for the data clustering.
We also used direct standardisation26 to remove differ-
ences in the age and sex distributions across the three 
groups of patients. Specifically, age was categorised 
into eight groups (18–24, 25–34, 35–44,…, 75–84 and 
85+) and the cohort of patients with no history of SMI 
nor depression was treated as the reference population. 
The standardisation was carried out separately for each 
calendar year.
All analyses were performed using Stata V.14.27
Patient and public involvement
Two people with lived experience (GC and LC, coau-
thors) were involved from the inception of the study, 
including informing the idea, the design and protocol 
for the funder. They actively contributed throughout, 
attending study meetings, contributing to the inter-
pretation of the findings and commenting on drafts of 
the paper. This included highlighting ongoing miscon-
ceptions around the safety of varenicline/bupropion in 
people with mental health problems and the importance 
of the quality of advice given for smoking cessation in the 
context of ongoing mental health symptoms.
RESULTS
Between 1 January 2007 and 31 December 2014, there 
were 882 849 patients who met the inclusion criteria and 
had at least one smoking status update to current smoker. 
Table 1 reports descriptive statistics for these patients, 
stratified by mental health condition. Smokers with a 
history of SMI tended to be older than other smokers.
Smoking cessation interventions
The proportions of patients who were advised to quit, 
received referrals to stop- smoking services or were 
prescribed cessation medication within 6 months from 
the index date are displayed in figure 1 by calendar year 
and mental health group. The corresponding numeric 
values and 95% CIs are reported in table 2. Age and 
gender standardisation of these proportions did not lead 
to significantly different findings so, for simplicity, only 
the unstandardised results are reported hereafter.
Advice to quit smoking
The majority (>70%) of the smokers who entered our 
study received advice to quit within 6 months from 
the index smoking status update, with the proportion 
reaching 80% among those with a history of SMI. When we 
looked at trends over time we observed similar patterns in 
the annual percentages of smokers advised to quit among 
those with depression and those with no mental health 
problems, with a steep increase between 2011 and 2012. 
The corresponding percentages for people with SMI 
were consistently higher than in the other two cohorts 
of patients across the whole study period but differences 
greatly reduced after 2012.
Referrals to smoking cessation services
The proportion of current smokers recorded as being 
referred to stop- smoking services was very low (<5%). A 
Figure 1 Annual proportions of smokers who received smoking cessation interventions within 6 months from the index 
smoking status update. Proportions are plotted by mental health condition and in relation to the calendar year in which the 
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small increase was observed over time, with the propor-
tion for example for those with depression increasing 
from 1.7% in 2007 to 4.3% in 2014, but no significant 
differences were found when comparing those with SMI 
or depression and those without.
Smoking cessation pharmacotherapy
Overall, NRT was the medication most commonly 
prescribed for smoking cessation within primary care. 
The proportion of current smokers who had prescriptions 
for NRT during the 6 months from when their smoking 
status was updated was 10.1% among the patients with a 
history of SMI, 8.7% among those with depression and 
5.9% among the general population without depression 
or SMI. In contrast, rates of varenicline or bupropion 
prescribing were very low, especially in the SMI group. 
When we examined temporal changes of pharmaco-
therapy prescribing, we observed a clear decline over 
time in the proportion of smokers who were prescribed 
NRT by their GP, with rates of prescribing of NRT consis-
tently higher in those with SMI and depression than the 
general population without these conditions.
Evidence of attempts to quit smoking
The proportions of smokers for whom we have evidence 
of quit attempts or who had a change of smoking status 
during the 6 months following their smoking status update 
are displayed in figure 2 and are reported in table 3 along 
with the 95% CIs. Age- standardised and sex- standardised 
proportions were derived but they did not significantly 
alter our findings so, as for the smoking cessation inter-
ventions, they are here omitted.
Table 2 Annual proportions (and 95% CIs) of smokers who received smoking cessation interventions within 6 months from 
the index date
Advice to quit smoking
Referrals to smoking 
cessation services Smoking cessation drug therapy








  2007 73.39 (70.88 to 75.77) 2.09 (1.50 to 2.88) 12.34 (11.05 to 13.76) 0.38 (0.20 to 0.71) 1.04 (0.65 to 1.66)
  2008 79.07 (76.79 to 81.18) 2.57 (1.50 to 4.37) 11.26 (9.78 to 12.92) 0.16 (0.05 to 0.51) 1.37 (0.91 to 2.04)
  2009 80.48 (78.22 to 82.56) 1.79 (1.10 to 2.90) 11.07 (9.74 to 12.56) 0.06 (0.01 to 0.40) 1.45 (0.97 to 2.17)
  2010 81.37 (78.89 to 83.62) 2.39 (1.64 to 3.48) 10.54 (9.06 to 12.24) 0.19 (0.06 to 0.60) 1.29 (0.76 to 2.18)
  2011 80.43 (77.81 to 82.81) 1.88 (1.24 to 2.82) 9.85 (8.31 to 11.64) 0.07 (0.01 to 0.48) 1.54 (1.05 to 2.27)
  2012 83.83 (81.57 to 85.85) 3.37 (2.31 to 4.89) 8.95 (7.42 to 10.75) 0.14 (0.03 to 0.54) 1.24 (0.79 to 1.95)
  2013 85.47 (83.27 to 87.42) 3.12 (2.13 to 4.54) 7.23 (5.98 to 8.71) 0.14 (0.04 to 0.56) 1.35 (0.85 to 2.12)
  2014 80.60 (77.61 to 83.28) 3.62 (2.41 to 5.40) 6.29 (4.95 to 7.96) 0.09 (0.01 to 0.61) 1.55 (1.00 to 2.40)
Depression
  2007 69.14 (67.39 to 70.83) 1.69 (1.29 to 2.21) 11.94 (11.08 to 12.86) 0.95 (0.78 to 1.16) 2.44 (2.03 to 2.94)
  2008 69.71 (67.87 to 71.49) 1.98 (1.42 to 2.77) 9.40 (8.55 to 10.33) 0.68 (0.51 to 0.90) 2.94 (2.49 to 3.48)
  2009 69.83 (68.02 to 71.58) 1.81 (1.43 to 2.30) 9.96 (9.12 to 10.86) 0.38 (0.26 to 0.55) 2.87 (2.44 to 3.36)
  2010 69.58 (67.68 to 71.42) 2.58 (1.97 to 3.37) 8.74 (7.84 to 9.73) 0.36 (0.23 to 0.56) 3.34 (2.91 to 3.82)
  2011 70.78 (68.93 to 72.57) 1.85 (1.32 to 2.60) 9.83 (8.87 to 10.87) 0.25 (0.15 to 0.41) 3.88 (3.35 to 4.48)
  2012 80.60 (79.09 to 82.02) 3.09 (2.34 to 4.06) 7.27 (6.55 to 8.07) 0.24 (0.15 to 0.39) 2.80 (2.42 to 3.24)
  2013 79.83 (78.26 to 81.32) 3.80 (2.95 to 4.87) 5.65 (4.96 to 6.42) 0.16 (0.09 to 0.28) 2.65 (2.23 to 3.15)
  2014 78.81 (76.79 to 80.70) 4.28 (3.19 to 5.72) 4.51 (3.79 to 5.36) 0.13 (0.06 to 0.28) 2.21 (1.80 to 2.72)
No SMI nor 
depression
  2007 67.63 (66.10 to 69.12) 1.60 (1.31 to 1.96) 8.26 (7.81 to 8.73) 1.16 (1.06 to 1.26) 2.26 (1.99 to 2.57)
  2008 66.97 (65.45 to 68.46) 1.65 (1.26 to 2.16) 6.38 (5.99 to 6.78) 0.60 (0.52 to 0.69) 2.98 (2.71 to 3.28)
  2009 67.43 (65.93 to 68.90) 1.47 (1.23 to 1.76) 6.50 (6.11 to 6.92) 0.43 (0.36 to 0.50) 3.77 (3.49 to 4.07)
  2010 67.22 (65.81 to 68.59) 1.73 (1.34 to 2.22) 6.20 (5.79 to 6.63) 0.33 (0.27 to 0.41) 4.62 (4.32 to 4.94)
  2011 67.65 (66.05 to 69.21) 1.80 (1.40 to 2.31) 6.06 (5.64 to 6.50) 0.24 (0.19 to 0.30) 4.51 (4.22 to 4.82)
  2012 76.56 (75.21 to 77.87) 3.09 (2.41 to 3.94) 4.86 (4.49 to 5.25) 0.14 (0.10 to 0.18) 3.87 (3.62 to 4.14)
  2013 76.78 (75.32 to 78.19) 3.21 (2.50 to 4.12) 3.70 (3.41 to 4.02) 0.11 (0.08 to 0.14) 3.12 (2.89 to 3.36)
  2014 76.11 (74.5 to 77.66) 3.43 (2.62 to 4.48) 3.12 (2.82 to 3.45) 0.09 (0.07 to 0.12) 2.71 (2.48 to 2.96)
Proportions are reported by mental health condition and in relation to the calendar year in which the index event was recorded.
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Recorded quit attempts
Overall, smokers with recognised poor mental health 
were more likely than those without mental ill- health to 
have at least one quit attempt (defined by either codes 
of quit attempts or other evidence of attempted quitting, 
such as the prescription of smoking cessation medica-
tion) recorded during the 6 months after the index date. 
This was also observed across all the time points, although 
the gap reduced towards the end of the study period. In 
all three cohorts of smokers, the annual proportions of 
people with recorded quit attempts showed a reduction 
after 2012. In a supplementary analysis where we inves-
tigated the single components defining a recorded quit 
attempt we found that this reduction was mainly driven 
by the decline in NRT prescribing by GPs over this time.
Changes of smoking status
Changes of smoking status recorded within 6 months 
from the index smoking status update were observed 
in 5.7% of smokers with SMI as compared with 5.9% 
among those with depression and 6.4% among the other 
smokers. The time trends of these proportions remained 
fairly stable and did not show large differences across the 
three cohorts of smokers.
DISCUSSION
Our study shows that most GPs recorded providing 
smoking cessation advice to patients who are identified 
as current smokers, although the duration and quality of 
the advice provided cannot be determined from our data. 
Rates of recorded smoking cessation advice in UK primary 
care were high for all three groups of patients and highest 
in those with SMI. However, increases in smoking cessa-
tion advice over time were not accompanied by increases 
in the prescription of smoking cessation medication, 
recorded quit attempts or changes in smoking status. 
Few people (<5%) were recorded as being referred to 
smoking cessation services, with a small upward trend 
over time, but no significant differences were observed 
between those with and without mental health condi-
tions. NRT prescribing by GPs was higher in smokers with 
SMI and depression, although it declined over time in all 
groups. Varenicline and bupropion prescribing was very 
low, and less common in those with SMI.
There were temporal trends in recorded smoking 
cessation interventions in primary care. We observed 
a steep increase in recorded advice between 2011 and 
2012, particularly for those without SMI (including those 
with depression). The percentage of smokers with SMI 
recorded as having received smoking cessation advice 
was consistently higher than in the other two cohorts of 
patients across the whole study period but differences 
observed greatly reduced after 2012. Studies in the USA 
have similarly found higher rates of smoking cessation 
advice given to smokers with SMI.28 The increase in advice 
to quit smoking given to non- SMI populations post 2012 
in our study may be due to changes in incentivisation of 
recording of smoking advice in England. Before 2012, 
the QOF incentives scheme rewarded GPs for providing 
smoking cessation advice but this was only in relation to 
smokers with specific medical conditions, which included 
those with SMI (but not depression) from 2006. In April 
2012, a new incentive was introduced to encourage GPs 
to provide smoking cessation support and treatment to all 
current smokers aged 15 years or over, regardless of their 
medical history. This incentivisation seems to have worked 
to increase the recording (and one presumes delivery) of 
smoking cessation advice by GPs and recorded referrals 
to smoking cessation services.29 However, our findings 
demonstrated no corresponding rise in prescribing of 
smoking cessation medication, quit attempts or changes 
in smoking status over the same time period, suggesting 
that this rising reported cessation advice was not effective 
in influencing quit rates. From our data we cannot deter-
mine the quality of advice given, but it is likely to be brief 
when opportunistic, and qualitative research has found 
Figure 2 Annual proportions of smokers with quit attempts or changes of smoking status recorded within 6 months from the 
index smoking status update. Proportions are plotted by mental health condition and in relation to the calendar year in which 
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that it can be confrontational in approach.30 Previous 
research has also shown that primary care physicians 
are more likely to ‘Ask’ (ask all patients about tobacco 
use) and ‘Advise’ (advise all tobacco users to quit) than 
they are to ‘Assess’ (assess the willingness to quit), ‘Assist’ 
(assist with quitting) or ‘Arrange’ (arrange follow- up) as 
part of the 5A’s strategy to support smoking cessation.31 
Our findings support that these latter steps—assessing 
motivation to quit, providing assistance and follow- up—
may be key missing steps in supporting people with 
mental health conditions to quit.32
The number of recorded quit attempts in our study had, 
if anything, a downward trend. However, this appeared to 
be explained by reducing rates of NRT prescribing by GPs, 
which in turn may be driven by a corresponding rise in 
NRT uptake outside of primary care and increasing popu-
larity of e- cigarettes. Our data source does not contain 
information on over- the- counter medication. Previous 
research has shown that the use of e- cigarettes in smokers 
increased between 2011 and 2013 and then levelled off 
afterwards.33 Beard et al reported that, after adjusting for 
confounding, the use of e- cigarettes for quitting was nega-
tively associated with NRT on prescription.34 We found 
that NRT prescribing was higher in those with depres-
sion and SMI than the general population without these 
conditions, which could be explained by corresponding 
lower prescribing of bupropion or varenicline (in those 
with SMI) or by higher attendance rates at GPs in these 
groups (increasing accessibility to NRT via GPs) or higher 
levels of unemployment and associated free prescriptions 
for NRT which they may otherwise need to purchase.
In all three groups in our study, the proportion of 
people who changed their recorded smoking status from 
current smoker to ex- smoker was lower in 2014 than 
in 2007 suggesting that, while other evidence indicates 
uptake of smoking is going down (proportions of never 
smokers are increasing over time in England)35 thus 
reducing overall smoking prevalence, in those that do 
smoke slightly fewer are quitting than in previous years. 
We found no major differences in changes of recorded 
smoking status from current to ex- smoker (indicating 
a successful quit attempt) in those with mental health 
conditions compared with the general population, which 
is in contrast to other evidence suggesting quit rates may 
be lower in those with SMI.36 This might be explained by 
an under- recording of smoking status changes in those 
without mental health conditions as they visit their GP 
less frequently.
Rates of prescribing of varenicline and bupropion 
were very low overall, and even lower for those with SMI, 
despite good evidence of effectiveness of both drugs in 
those with SMI in increasing medium- long term quit 
rates37 38 and some evidence that varenicline may be 
more effective than NRT.39 40 Low prescribing probably 
reflects concerns among GPs and patients regarding 
the side effects of these two drugs during this period. 
In 2007, the US Food and Drug Administration (FDA) 
announced investigations into the safety of varenicline 
following concerns related to suicidality and other neuro-
psychiatric adverse events. Similar concerns were subse-
quently raised for bupropion too, prompting the FDA to 
issue in 2009 a black- box warning (the FDA’s most serious 
type of warning) for both varenicline and bupropion. 
Subsequent studies including large scale trials found 
no evidence to support these concerns36 41 42; however, 
the FDA warning for possible serious neuropsychiatric 
adverse events in patients quitting smoking was not 
removed until December 2016. Information campaigns 
may be needed for both smokers with mental health 
Table 3 Annual proportions (and 95% CIs) of smokers with 
quit attempts or a change of smoking status recorded within 
6 months from the index smoking status update
Recorded quit 
attempts




  2007 19.56 (17.98 to 21.24) 6.13 (5.13 to 7.31)
  2008 19.07 (17.05 to 21.27) 6.12 (4.98 to 7.50)
  2009 18.79 (16.82 to 20.94) 5.59 (4.68 to 6.67)
  2010 18.95 (16.90 to 21.19) 5.43 (4.36 to 6.75)
  2011 18.63 (16.62 to 20.83) 6.77 (5.63 to 8.12)
  2012 17.69 (15.55 to 20.05) 5.09 (4.09 to 6.33)
  2013 16.16 (14.05 to 18.52) 4.61 (3.61 to 5.86)
  2014 15.95 (13.69 to 18.50) 5.69 (4.47 to 7.22)
Depression
  2007 20.20 (19.13 to 21.31) 6.46 (5.87 to 7.11)
  2008 18.32 (17.09 to 19.61) 5.73 (5.21 to 6.30)
  2009 18.29 (17.17 to 19.47) 5.70 (5.10 to 6.38)
  2010 18.15 (16.95 to 19.42) 5.38 (4.84 to 5.96)
  2011 19.09 (17.90 to 20.34) 6.01 (5.43 to 6.65)
  2012 18.29 (17.09 to 19.55) 6.02 (5.46 to 6.63)
  2013 17.02 (15.73 to 18.40) 6.15 (5.61 to 6.75)
  2014 14.59 (13.18 to 16.12) 4.92 (4.31 to 5.61)
No SMI nor 
depression
  2007 17.64 (16.97 to 18.34) 7.31 (7.01 to 7.63)
  2008 15.97 (15.20 to 16.77) 6.36 (6.06 to 6.66)
  2009 16.36 (15.66 to 17.08) 6.36 (6.07 to 6.65)
  2010 16.82 (16.11 to 17.56) 6.15 (5.85 to 6.46)
  2011 16.68 (16.00 to 17.37) 6.22 (5.91 to 6.55)
  2012 17.14 (16.26 to 18.06) 6.62 (6.34 to 6.92)
  2013 15.19 (14.32 to 16.10) 5.91 (5.64 to 6.20)
  2014 13.84 (12.84 to 14.90) 5.22 (4.95 to 5.50)
Proportions are reported by mental health condition and are 
derived in relation to the calendar year in which the index date 
falls.
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conditions and primary care providers to address this and 
encourage a greater uptake of prescribing of these drugs 
in people with mental health problems.
To our knowledge, this is the first study to explore time 
trends across a range of primary care management strat-
egies for smoking cessation in people with mental health 
conditions using a large nationally representative dataset. 
As a study of routinely collected primary care data there 
are some inherent limitations, the key one being that we 
were only able to include pharmacotherapy prescribed 
by GPs and had no information on over- the- counter 
treatments, including the rising use of e- cigarettes. 
There is evidence however that recorded prescriptions 
for smoking cessation medication are comparable to 
national dispensing data and are a valid source for moni-
toring trends in prescribing for smoking cessation.43 We 
are only able to report on recorded data, and some inter-
ventions (eg, advice) may occur but are not entered into 
the patient’s record. However, information on prescrip-
tion is of high quality in THIN and recorded advice levels 
were very high, suggesting that this was not a significant 
problem, though changes in recording practices over 
time may explain some of the patterns we observed. The 
prescribing records in our data source represent prescrip-
tions issued by GP practices, and patients may not go on to 
take these medications. We included the issue of smoking 
cessation medication as an indicator of a ‘quit attempt’ 
(an intention to try to quit) and this may overestimate 
true quit attempts as not all patients will actually carry on 
to try stopping smoking. It is quite likely, nonetheless, that 
quit attempts were under- recorded as many people will 
not report this to their GP. Changes to smoking status will 
also depend on the GP becoming aware of this during the 
follow- up period, meaning that these may also be under- 
recorded. As those with mental health conditions visit 
their GP more often, there are more opportunities for 
them to receive smoking cessation support in this setting 
and it is possible that this explains the slightly higher 
recorded NRT prescribing observed in this group. This 
is not necessarily an indicator of better quality smoking 
cessation support in these populations.
Our results show that while smoking cessation advice 
is both very high and recorded as being offered more 
frequently in those with SMI this gap has narrowed 
in more recent years (probably due to changes in how 
recording of smoking cessation advice is incentivised), 
and changes in levels of advice is not linked to corre-
sponding changes in quit attempts or smoking status. 
This is of concern given the ongoing high smoking rates 
in those with poor mental health, particularly those with 
SMI.44 There is some evidence that better quit rates can 
be achieved when smoking cessation is integrated within 
specialist mental healthcare settings45 or with the addition 
of spirometry and feedback on lung age and degree of 
airways obstruction.46 Our findings suggest that in order 
to close the widening gap in smoking prevalence and its 
consequences for people with mental health conditions, 
the focus in primary care should change from the quantity 
of advice given to the quality. This should include routine 
assessment of willingness to change, greater provision 
of assistance to quit and arranging follow- up as part of a 
‘5As’ strategy31 and could include other elements such as 
spirometry with feedback to better support smoking cessa-
tion in people with mental health conditions. Incentivisa-
tion schemes for GPs should reflect this, in particular as 
due to funding restraints this is often the main source of 
smoking cessation support for people with mental health 
conditions.
CONCLUSIONS
Recorded smoking cessation advice delivered by GPs 
was very high at times when GPs reviewed an individu-
al’s smoking status, and higher in those with SMI. We 
found no evidence of consistent inequalities in access 
to smoking cessation interventions in primary care 
for people with recognised mental illness. In order to 
address the widening gap in smoking prevalence in those 
with poor mental health compared with those without, 
the emphasis should now be on addressing the quality of 
advice and support provided in primary care.
Twitter David Osborn @oosborn_ucl
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